Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation

Cambridge, UK: 10 April 2024

One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Melanie Leveridge, Vice President, Assays, Profiling & Cell Sciences, AstraZeneca, as a Non-Executive Director.

Melanie is an established preclinical drug discovery leader with a track record of developing and inspiring diverse, high performing teams, to deliver innovative science and technology. Melanie joined AstraZeneca in April 2024 as Vice President of Assays, Profiling and Cell Sciences within the Discovery Sciences organisation. In this role she leads a team of 200 scientists accountable for generation of cellular reagents, assay development, compound profiling and mechanism of action studies, partnering closely with the Therapy Areas to deliver hits, leads and candidates to progress AstraZeneca’s discovery portfolio.

Prior to her time at AstraZeneca, Mel spent 19 years at GSK, during which time she held a variety of roles in early discovery, including 9 years as Senior Director of Screening, Profiling and Mechanistic Biology and head of GSK’s global Sample Management teams. Outside of AstraZeneca, Mel is a Society for Lab Automation and Screening (SLAS) Fellow and has just completed a four-year term as Chair of the Board for ELRIG UK, a not-for-profit organisation which delivers conferences and educational content to the life sciences community on an open access basis.

Tony Jones, Chief Executive, One Nucleus explained: “Melanie will be an excellent addition to the One Nucleus Board. Not only bringing extensive knowledge of the needs of growing life science companies, Melanie has true depth in understanding how the sector is evolving with technology playing an increasingly important role in the development of better medicines and interventions for patients.  Melanie will play a vital role as we continue the development of One Nucleus as the go to organisation for those seeking to engage with and support Life Sciences in our region”.

Commenting on her appointment Melanie said: “I very much look forward to working with One Nucleus and its members, to support their future objectives. These are exciting times for the sector and One Nucleus is extremely well placed to connect and champion the cluster in order to catalyse business creation and growth. I am delighted to have been asked to join the Board and look forward to bringing my experience to the table, to support the team and assist One Nucleus members.”

Ends
 

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.